Novigenix’s LITOSeek™, powered by AI and RNA analysis, represents a significant advancement in personalized cancer treatment and drug development. It offers the potential to reshape how biopharma companies approach therapeutic discoveries in the field.
Personalized Cancer Treatment: Novigenix focuses on improving cancer treatment by leveraging advanced AI and RNA analysis from routine blood draws. This approach provides more precise insights into patient immune responses to cancer treatments compared to conventional DNA liquid biopsies.
Introduction of LITOSeek™: Novigenix will debut LITOSeek™ at the Precision Medicine World Conference in Silicon Valley. LITOSeek™ is a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis in Healthcare: Novigenix has a decade-long track record in AI and RNA analysis, demonstrated by the successful launch of the Colox® blood test in Switzerland for early-stage colon cancer detection. This test marked a significant departure from invasive colonoscopy procedures.
Potential of AI RNA Analysis: Dr. Brian Hashemi, CEO and Chairman of Novigenix, emphasized the potential of AI RNA analysis in uncovering comprehensive sets of biomarkers via liquid biopsy. The company’s validated immunotherapy response biomarkers provide early prediction of patient response, which can be leveraged by biopharma companies for more efficient and effective drug development.
Impact on Conventional Drug Development: Professor Pedro Romero, Chief Medical & Scientific Officer of Novigenix, highlighted that AI RNA analysis could revolutionize healthcare by accelerating conventional experimental drug development with data-driven precision immune response prediction.
Dedicated Team and Focus: Novigenix has over 20 Ph.D.-level scientists focused on developing the LITOSeek™ platform and advancing next-generation liquid biopsy solutions. The company is pioneering precision immunology to transform cancer treatment paradigms for better patient outcomes.